{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:20:20Z","timestamp":1740144020049,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40256-023-00571-y","type":"journal-article","created":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T18:03:01Z","timestamp":1675533781000},"page":"185-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictors of Poor Very Early Diuretic Response and Effectiveness of Early Tolvaptan in Symptomatic Acute Heart Failure"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5245-5451","authenticated-orcid":false,"given":"Hideyuki","family":"Takimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsumasa","family":"Kurozumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rintaro","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ippei","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mami","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukako","family":"Takimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko","family":"Tsukahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,4]]},"reference":[{"key":"571_CR1","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","volume":"391","author":"N Conrad","year":"2018","unstructured":"Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391:572\u201380.","journal-title":"Lancet"},{"key":"571_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ahj.2004.08.005","volume":"149","author":"KF Adams","year":"2005","unstructured":"Adams KF, Fonarow GC, Emerman CL, LeJemtel TH, Cost-anzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209\u201316.","journal-title":"Am Heart J"},{"key":"571_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/ejhf.74","volume":"16","author":"RJ Mentz","year":"2014","unstructured":"Mentz RJ, Kjeldsen K, Rossi GP, Voors AA, Cleland JG, Anker SD, et al. Decongestion in acute heart failure. Eur J Heart Fail. 2014;16:471\u201382.","journal-title":"Eur J Heart Fail"},{"key":"571_CR4","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726.","journal-title":"Eur Heart J"},{"key":"571_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1161\/CIRCULATIONAHA.109.933275","volume":"122","author":"JM Testani","year":"2010","unstructured":"Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122:265\u201372.","journal-title":"Circulation"},{"key":"571_CR6","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.jacc.2012.12.050","volume":"61","author":"MP Van Der","year":"2013","unstructured":"Van Der MP, Postmus D, Ponikowski P, Cleland JG, O\u2019Connor CM, Cotter G, et al. The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. J Am Coll Cardiol. 2013;61:1973\u201381.","journal-title":"J Am Coll Cardiol"},{"key":"571_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCHEARTFAILURE.111.963413","volume":"5","author":"M Metra","year":"2012","unstructured":"Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail. 2012;5:54\u201362.","journal-title":"Circ Heart Fail"},{"key":"571_CR8","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1016\/j.jacc.2017.04.042","volume":"69","author":"Y Matsue","year":"2017","unstructured":"Matsue Y, Damman K, Voors AA, Kagiyama N, Yamaguchi T, Kuroda S, et al. Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69:3042\u201351.","journal-title":"J Am Coll Cardiol"},{"key":"571_CR9","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1093\/eurheartj\/ehu065","volume":"35","author":"MAE Valente","year":"2014","unstructured":"Valente MAE, Voors AA, Damman K, Van VDJ, Massie BM, O\u2019Connor CM, et al. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J. 2014;35:1284\u201393.","journal-title":"Eur Heart J"},{"key":"571_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0735-1097(03)00765-4","volume":"42","author":"M Domanski","year":"2003","unstructured":"Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"571_CR11","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/eurheartj\/ehi890","volume":"27","author":"A Ahmed","year":"2006","unstructured":"Ahmed A, Husain A, Love TE, Gambassi G, Dell\u2019Italia LJ, Francis GS, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J. 2006;27:1431\u20139.","journal-title":"Eur Heart J"},{"key":"571_CR12","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam MA, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, et al. An oral vasopressin antagonist, in patients hospitalized for heart failure. JAMA. 2007;297:1332\u201343.","journal-title":"JAMA"},{"key":"571_CR13","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1007\/s00380-015-0775-9","volume":"31","author":"Y Uemura","year":"2016","unstructured":"Uemura Y, Shibata R, Takemoto K, Uchikawa T, Koyasu M, Ishikawa S, et al. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease. Heart Vessels. 2016;31:1643\u20139.","journal-title":"Heart Vessels"},{"issue":"1","key":"571_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1253\/circj.CJ-17-0179","volume":"82","author":"T Inomata","year":"2017","unstructured":"Inomata T, Ikeda Y, Kida K, Shibagaki Y, Sato N, Kumagai Y, et al. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment\u2014results from the K-STAR study. Circ J. 2017;82(1):159\u201367.","journal-title":"Circ J"},{"issue":"6","key":"571_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cardfail.2016.02.007","volume":"22","author":"Y Matsue","year":"2016","unstructured":"Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, et al. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction\u2014AQUAMARINE study. J Card Fail. 2016;22(6):423\u201332.","journal-title":"J Card Fail"},{"key":"571_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11255-019-02180-8","volume":"51","author":"T Masuda","year":"2019","unstructured":"Masuda T, Ohara K, Nagayama I, Matsuoka R, Murakami T, Nakagawa S, et al. Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients. Int Urol Nephrol. 2019;51:9.","journal-title":"Int Urol Nephrol"},{"key":"571_CR17","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1097\/01.CCM.0000296274.51933.4C","volume":"36","author":"A Mebazaa","year":"2008","unstructured":"Mebazaa A, Gheorghiade M, Pi\u00f1a IL, Harjola V-P, Hollenberg SM, Follath F, et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med. 2008;36:S129\u201339.","journal-title":"Crit Care Med"},{"key":"571_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1161\/01.CIR.88.1.107","volume":"88","author":"KKL Ho","year":"1993","unstructured":"Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation. 1993;88:107\u201315.","journal-title":"Circulation"},{"key":"571_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/cc5713","volume":"11","author":"RL Mehta","year":"2007","unstructured":"Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:1\u20138.","journal-title":"Crit Care"},{"key":"571_CR20","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.amjcard.2017.03.030","volume":"119","author":"S Aoki","year":"2017","unstructured":"Aoki S, Okumura T, Sawamura A, Kitagawa K, Morimoto R, Sakakibara M, et al. Usefulness of the combination of in-hospital poor diuretic response and systemic congestion to predict future cardiac events in patients with acute decompensated heart failure. Am J Cardiol. 2017;119:2010\u20136.","journal-title":"Am J Cardiol"},{"key":"571_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00392-015-0896-2","volume":"105","author":"JM ter Maaten","year":"2016","unstructured":"ter Maaten JM, Valente MAE, Metra M, Bruno N, O\u2019Connor CM, Ponikowski P, et al. A combined clinical and biomarker approach to predict diuretic response in acute heart failure. Clin Res Cardiol. 2016;105:145\u201353.","journal-title":"Clin Res Cardiol"},{"key":"571_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ejhf.1369","volume":"21","author":"W Mullens","year":"2019","unstructured":"Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al. The use of diuretics in heart failure with congestion\u2014a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:137\u201355.","journal-title":"Eur J Heart Fail"},{"key":"571_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/CIRCHEARTFAILURE.115.002370","volume":"9","author":"JM Testani","year":"2016","unstructured":"Testani JM, Hanberg JS, Cheng S, Rao V, Onyebeke C, Laur O, et al. Rapid and highly accurate prediction of poor loop diuretic natriuretic response in patients with heart failure. Circ Heart Fail. 2016;9:1\u20138.","journal-title":"Circ Heart Fail"},{"key":"571_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cardfail.2018.09.004","volume":"25","author":"S Kuroda","year":"2019","unstructured":"Kuroda S, Damman K, ter Maaten JM, Voors AA, Okumura T, Kida K, et al. Very early diuretic response after admission for acute heart failure. J Card Fail. 2019;25:12\u20139.","journal-title":"J Card Fail"},{"key":"571_CR25","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/ehf2.13139","volume":"8","author":"Y Shiraishi","year":"2021","unstructured":"Shiraishi Y, Kawana M, Nakata J, Sato N, Fukuda K, Kohsaka S. Time-sensitive approach in the management of acute heart failure. ESC Heart Fail. 2021;8:204\u201321.","journal-title":"ESC Heart Fail"},{"key":"571_CR26","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/ejhf.170","volume":"16","author":"AA Voors","year":"2014","unstructured":"Voors AA, Davison BA, Teerlink JR, Felker GM, Cotter G, Filippatos G, et al. Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome\u2014an analysis from RELAX-AHF. Eur J Heart Fail. 2014;16:1230\u201340.","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"571_CR27","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Mag-gioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA. 2007;297(12):1332\u201343.","journal-title":"JAMA"},{"key":"571_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jjcc.2012.08.020","volume":"61","author":"Y Matsue","year":"2013","unstructured":"Matsue Y, Suzuki M, Seya M, Iwatsuka R, Mizukami A, Nagahori W, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol. 2013;61:169\u201374.","journal-title":"J Cardiol"},{"key":"571_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ehf2.12088","volume":"3","author":"K Jujo","year":"2016","unstructured":"Jujo K, Saito K, Ishida I, Furuki Y, Kim A, Suzuki Y, et al. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail. 2016;3:177\u201388.","journal-title":"ESC Heart Fail"},{"key":"571_CR30","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9880.1000395","author":"T Hideyuki","year":"2015","unstructured":"Hideyuki T, Toshiya M, Tsuyoshi S, Masahiro Y, Norihiro K. Efficacy and safety of coadministration of tolvaptan and carperitide for acute decompensated heart failure patients. J Clin Exp Cardiol. 2015. https:\/\/doi.org\/10.4172\/2155-9880.1000395.","journal-title":"J Clin Exp Cardiol"},{"key":"571_CR31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000047397","volume":"96","author":"DH Ellison","year":"2001","unstructured":"Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96:132\u201343.","journal-title":"Cardiology"},{"key":"571_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJM199808063390607","volume":"339","author":"DC Brater","year":"1998","unstructured":"Brater DC. Diuretic therapy. N Engl J Med. 1998;339:387\u201395.","journal-title":"N Engl J Med"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-023-00571-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-023-00571-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-023-00571-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T15:36:45Z","timestamp":1678462605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-023-00571-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["571"],"URL":"https:\/\/doi.org\/10.1007\/s40256-023-00571-y","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2023,2,4]]},"assertion":[{"value":"18 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funds were used in the conduct of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hideyuki Takimura received lecture honoraria from Otsuka Pharmaceutical Co. and Novartis Pharma Co. Atsumasa Kurozumi, Rintaro Taniguchi, Ippei Tsuzuki, Emi Tajima, Yukihiro Yamaguchi, Mami Kawano, Yukako Takimura, Satoru Nishio, Masatsugu Nakano, and Reiko Tsukahara declare they have no potential conflicts of interest that might be relevant to this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was executed in compliance with the Declaration of Helsinki regarding investigations in human subjects, and the study protocol was approved by the Ethics Committee of the Tokyo General Hospital.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"HT and MN made substantial contributions to the study concept and design. Data collection was undertaken by HT, AK, and ET. YT and SN analyzed all data. MK approved the statistical analysis. RT, IT, YY and RT supervised the project and reviewed the manuscript. HT, AK, MN and RT prepared the manuscript. All authors approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}